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Table 1. Sensitivity and Specificity of the FRAX Algorithm to Predict Fracture Risks,
Computed With or Without Human Immunodeficiency Virus (HIV) Infection Considered
as a Secondary Cause of Osteoporosis
Patients’ BMD
No. of patients with
risk levels above
assessment threshold
No. of patients with
risk levels above
intervention threshold
Fracture
risk without
HIV
Fracture
risk with
HIV
Fracture
risk without
HIV
Fracture
risk with
HIV
5% !5% 5% !5% 7.5% !7.5% 7.5% !7.5%
Low ( )np 65 25 40 33 32 11 54 23 42
Normal ( )np 74 34 40 38 36 8 66 27 47
Sensitivity or specificity, %a 39 54 51 49 17 89 35 64
NOTE. The assessment threshold is defined as a risk of major osteoporotic fracture of 5%. The
intervention threshold is defined as a risk of major osteoporotic fracture of 7.5%. BMD, bone mineral
density.
a Sensitivity for patients with risk levels at or above the threshold, and specificity for patients with risk
levels below the threshold.
Reply to Gazzola et al
To the Editor—We were interested to read
about additional experience with use of
the FRAX score among adults with human
immunodeficiency virus (HIV) infection.
Gazzola et al [1] demonstrated that the
FRAX score computed on the basis of only
classical risk factors had poor sensitivity
(22%) for identifying patients with low
bone mineral density (BMD; defined as a
T score of !1 and Z score of !1). The
sensitivity was only modestly improved
(37%) when HIV infection was included
in the FRAX score as a secondary cause
of osteoporosis.
In our article [2], we demonstrated that
the FRAX score computed without BMD
was not able to discriminate adequately
between HIV-infected adults with osteo-
penia and those without osteopenia, be-
cause the fracture risk level provided by
the FRAX score for patients with osteo-
penia was similar to that provided for pa-
tients without osteopenia.
We reanalyzed our cohort of 153 adults
(150 [98%] were male, 67 [44%] were re-
ceiving tenofovir, and 81 [53%] were re-
ceiving a ritonavir-boosted protease in-
hibitor; median age, 48 years) to assess the
role of HIV disease. When HIV infection
was included in the FRAX score as a sec-
ondary cause of osteoporosis, the FRAX
score was not able to discriminate between
patients with osteopenia and those with-
out osteopenia (data not shown).
In addition, we performed new analy-
ses on the sensitivity and the specificity
of adding HIV infection as a secondary
cause of osteoporosis to the FRAX score
computed without BMD, in predicting
the risk for a major osteoporotic fracture;
any risk of major osteoporotic fracture
above a threshold of 7.5% [3] or 20%
[4] at 10 years would warrant bisphos-
phonate treatment (intervention thresh-
old). Second, we also chose a threshold
that would warrant BMD assessment (as-
sessment threshold) when the risk of ma-
jor osteoporotic fracture would exceed
5% at 10 years [5].
Of the 65 patients with a low BMD, the
FRAX score computed without HIV in-
fection included as a secondary cause of
osteoporosis identified only 11 patients
(sensitivity, 17%) for whom bisphospho-
nate treatment would be appropriate (in-
tervention threshold, 7.5%). When HIV
infection was included in the FRAX score,
the sensitivity increased to 35%. Choosing
an intervention threshold of 20% dra-
matically decreased the sensitivity (3%
with and 1.5% without HIV infection as
a secondary cause; data not shown). We
found a similar difference in sensitivity
when the threshold was lowered to 5% in
order to identify patients who need a BMD
assessment: the sensitivity increased from
39% to 51% after the inclusion of HIV
infection as a secondary cause of osteo-
porosis (Table 1).
Therefore, the FRAX score appears to
be an imperfect tool for BMD screening
among HIV-infected adults who are re-
ceiving antiretroviral therapy: even when
HIV infection is included as a secondary
cause of osteoporosis, the score conser-
vatively assumes that the risk is exclusively
mediated by low BMD, which reflects the
data available for rheumatoid arthritis. In-
deed, when BMD is entered into the FRAX
equation, no weight is accorded to these
secondary causes, which may increase
bone fragility independently of BMD
losses. In addition, biochemical markers
for bone turnover are not incorporated
into assessment algorithms, but we and
others [6] have shown that patients re-
ceiving tenofovir were likely to have in-
creased bone turnover. Thus, the FRAX
tool is mainly limited, because it does not
recognize HIV infection as a possible cause
of bone fragility and because HIV infec-
tion may only be considered to have an
effect on fracture risk through an effect on
BMD loss. A model that would help pre-
dict who could benefit from dual-energy
x-ray absorptiometry assessment, and
therefore who would be eligible for a pre-
ventive therapeutic approach, is lacking.
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We do recognize, however, that routine
BMD assessment of all HIV-infected
adults by means of dual-energy x-ray ab-
sorptiometry may be impractical in many
settings.
In conclusion, no adequate tool is val-
idated to guide the clinicians in when to
perform a BMD assessment. If the FRAX
score is used to prompt the decision to
assess BMD, we suggest that HIV infection
be included as a secondary cause of os-
teoporosis but that clinicians keep in mind
that only 50% of the patients with low
BMD will be identified. Our data are in
line with those of Gazzola et al [1], and
we urge the development of a model for
fracture prediction that can be applied for
younger patients who are affected by
chronic diseases that are not included as
classical risk factors in the FRAX tool. Al-
ternatively, the guidelines recently issued
by the European AIDS Clinical Society [7]
recommend considering BMD measure-
ments for postmenopausal women, men
150 years of age, and patients with hy-
pogonadism, prolonged glucocorticoid
use, or a history of low-impact fracture or
a high risk of falls. Again, these risk factors
only identify a minority of the patients
with osteopenia.
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